

Role and Evidence for Triglyceride-rich Lipoprotein Management in Reducing CVD Residual Risk

November 11, 2018

|

Hyatt Regency McCormick Place

|

Chicago, IL

Agenda

- 6:30 PM **Registration**
- 7:00 **Buffet Dinner**
- 7:00 **Program Overview**
Peter Libby, MD, Co-Chair, and Michael Miller, MD, Co-Chair
- 7:10 **Central Role of Triglyceride-rich Lipoproteins (TGRL) in CVD Residual Risk beyond Statin Therapy**
Børge G. Nordestgaard, MD, DMSc
- 7:35 **Biologic Basis for TGRL Modulation in Reducing Atherosclerosis**
R. Preston Mason, PhD
- 8:00 **Clinical Evidence on Reducing TGRL-based Residual Risk**
Deepak L. Bhatt, MD, MPH
- 8:25 **Challenging Issues in Lipid Management**
All Faculty
- 8:45 **Q & A**
Faculty and Audience
- 9:00 PM **Adjourn**

Faculty slides are available online: events.medtelligence.net/HAHTG18f.html